(pan-i-tu-mu-mab) ,


(trade name)


Therapeutic: antineoplastics
Pharmacologic: monoclonal antibodies
Pregnancy Category: C


Treatment of metastatic colorectal cancer that expresses EGFR (epidermal growth factor receptor) and has failed conventional treatments (to be used as monotherapy).


genetic implication Binds to EGFR resulting in inactivation of kinases that regulate proliferation and transformation.

Therapeutic effects

Decreased progression of colorectal cancer.


Absorption: IV administration results in complete bioavailability.
Distribution: Monoclonal antibodies cross the placenta and enter breast milk.
Metabolism and Excretion: Unknown.
Half-life: 7.5 days.

Time/action profile

IVunknownend of infusionunknown


Contraindicated in: Concurrent leucovorin;genetic implication Patients whose tumors have KRAS mutations in codon 12 or 13 (not effective); Obstetric / Lactation: Pregnancy or lactation.
Use Cautiously in: Pediatric: Safety not established.

Adverse Reactions/Side Effects

Central nervous system

  • fatigue (most frequent)

Ear, Eye, Nose, Throat

  • ocular toxicity (life-threatening)
  • eyelash growth


  • pulmonary fibrosis (life-threatening)
  • cough (most frequent)


  • abdominal pain (most frequent)
  • constipation (most frequent)
  • diarrhea (most frequent)
  • nausea (most frequent)
  • vomiting (most frequent)
  • stomatitis


  • necrotizing fasciitis (life-threatening)
  • paromychia (most frequent)
  • abscesses
  • dry skin
  • erythema
  • photosensitivity
  • pruritis
  • rash
  • skin fissures

Fluid and Electrolyte

  • edema (most frequent)
  • hypocalcemia
  • hypomagnesemia (most frequent)


  • infusion reactions (life-threatening)
  • sepsis (life-threatening)


Drug-Drug interaction

None noted.


Intravenous (Adults) 6 mg/kg as a 60-min infusion every 14 days; ↓ infusion rates and dose modifications are recommended for infusion reactions and other serious toxicities.


Solution for IV administration (requires dilution): 20 mg/mL

Nursing implications

Nursing assessment

  • Assess for dermatologic toxicity (dermatitis acneiform, pruritus, erythema, rash, skin exfoliation, paronychia, dry skin, skin fissures). If severe, may lead to infection (sepsis, septic death, abscesses requiring incision and drainage). With severe reactions, withhold panitumumab and monitor for inflammatory or infectious sequelae.
  • Monitor for severe infusion reactions (anaphylactic reaction, bronchospasm, fever, chills, hypotension). If severe reaction occurs, stop panitumumab; may require permanent discontinuation.
  • Assess for pulmonary fibrosis (cough, wheezing, exertional dyspnea, interstitial lung disease, pneumonitis, lung infiltrates). Permanently discontinue panitumumab if these signs occur.
  • Monitor for diarrhea during therapy.
  • Lab Test Considerations: Monitor electrolyte levels periodically during and for 8 wk after completion of therapy. May cause hypomagnesemia and hypocalcemia.

Potential Nursing Diagnoses

Risk for impaired skin integrity (Adverse Reactions)
Impaired gas exchange (Adverse Reactions)


  • Intermittent Infusion: Diluent: Withdraw necessary amount of panitumumab. Dilute to a volume of 100 mL with 0.9% NaCl; dilute doses >1000 mg with 150 mL.Concentration: 10 mg/mL. Mix by inverting gently; do not shake. Administer via infusion pump using a low-protein binding 0.2 mcg or 0.22 mcg in-line filter. Solution is colorless and may contain a small amount of visible translucent to white, amorphous, proteinaceous particles. Do not administer solutions that are discolored or contain particulate matter. Store in refrigerator; do not freeze. Use diluted solution within 6 hr of preparation if stored at room temperature or within 24 hr if refrigerated.
  • Rate: Administer over 60 min every 14 days. Administer doses >1000 mg over 90 min.
    • If mild to moderate infusion reaction (Grade 1 or 2) occurs decrease infusion rate by 50%. If severe reaction (Grade 3 or 4) occurs, immediately and permanently discontinue panitumumab.
    • If severe dermatologic toxicities (Grade 3 or higher) or those considered intolerable occur, withhold panitumumab. If toxicity does not improve to ≤ grade 2 within 1 mo, discontinue permanently. If toxicity improves to ≤ grade 2 and patient improves symptomatically after withholding no more than 2 doses, resume therapy at 50% dose. If toxicities recur, permanently discontinue panitumumab. If toxicities do not recur, increase subsequent doses in 25% increments of the original dose until recommended dose of 6 mg/kg is reached.
  • Y-Site Incompatibility: Flush line before and after administration with 0.9% NaCl. Do not mix with other medications or solutions.

Patient/Family Teaching

  • Explain purpose of panitumumab to patient.
  • May cause photosensitivity. Caution patient to wear sunscreen and hats and to limit sun exposure.
  • Advise patient to notify health care professional if signs and symptoms of dermatologic toxicity, infusion reactions, pulmonary fibrosis, or ocular changes occur.
  • Advise patient that panitumumab may cause fertility impairment and may have teratogenic effects. Caution women of childbearing yr to use contraception during and for at least 6 mo after the last dose and not to breast feed during and for at least 2 mo after the last dose of panitumumab. Encourage women who become pregnant to enroll in Amgen’s Pregnancy Surveillance Program by calling 1-800-772-6436.
  • Emphasize the need for periodic blood tests to monitor electrolyte levels.

Evaluation/Desired Outcomes

  • Decreased progression of colorectal cancer.


a trademark for panitumumab.
Mentioned in ?
References in periodicals archive ?
Forecasts for nine leading drugs - discover sales potentials Our new investigation gives you revenue forecasts to 2025 for nine leading products for treating colorectal cancer: -- Avastin (Roche) -- Erbitux (BMS/Merck Serono) -- Xeloda (Roche) -- Vectibix (Amgen) -- Stivarga (Bayer) -- Eloxatin (Sanofi) -- TS-1 (Taiho Pharmaceuticals) -- Zaltrap (Sanofi) -- Cyramza (Eli Lilly)
Contract award: drug delivery alimta - l01ba04, copaxone 20 mg / ml -: l03ax13, enbrel - l04ab01, humira - l04ab04, iressa 250 mg - l01xe02, simponi 50 mg - l04ab06, vectibix 20 mg / ml - l01xc08.
Sales of Vectibix (panitumumab) increased 10 percent to $87 million in the fourth quarter of 2011 versus $79 million in the fourth quarter of 2010.
13) Studies show patients whose tumors express the mutated version of the KRAS gene will not respond to Erbitux or Vectibix.
The NHS drugs rationing body, the National Institute for Health and Clinical Excellence (Nice), has issued new draft guidance not recommending the use of the drugs Avastin, Erbitix and Vectibix for the treatment of metastatic bowel cancers - those that spread to the rest of the body after first line chemotherapy.
K-RAS has received increased attention in recent years, and validation from the American Society of Clinical Oncology, as an aid to choosing colorectal cancer patients to be treated with Eli Lilly /Bristol-Myers Squibb's Erbitux (cetuximab) or Amgen's Vectibix (panitumumab).
In the United States, Qiagen is the exclusive supplier of tests needed before Vectibix and Erbitux can be used, while in Europe it has an 80% market share, the CEO said.
Studies in pregnant animals with Herceptin and Rituxan suggested low risk for humans, whereas the suggested risk was higher for Avastin, Mylotarg, and Vectibix.
The recent announcement of Thousand Oaks, California-based Amgen's expenditure-limit policy for the colon cancer drug Vectibix (panitumumab) to aid patients who require the medication is an indication that PAPs are not only still needed, but may even be coming to the forefront of pharmaceutical companies' marketing efforts.
Food and Drug Administration approved its colorectal cancer fighter Vectibix.
Long-term survival data from the PEAK trial final analysis adds to the understanding of how Vectibix works when added to standard first-line chemotherapy for the treatment of wild-type RAS metastatic colorectal cancer.
The major biologics used for treating colorectal cancer include Erbitux (cetuximab), Zaltrap (ziv-Aflibercept), Avastin (bevacizumab), and Vectibix (panitumumab).